Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol-Myers Squibb plans to bring immunomodulator CTLA4Ig into Phase II this year for psoriasis.

Executive Summary

BRISTOL-MYERS SQUIBB TAKING IMMUNOMODULAR CTLA4Ig INTO PHASE II BY YEAR END to evaluate the drug's efficacy in psoriasis. CTLA4Ig is an immunomodulator that "essentially works by blocking the activation of immune system T cells, which prevents the body from recognizing transplanted tissue as foreign or mistakenly rejecting its own tissue," Bristol-Myers Squibb explains.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts